Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Carol Stiff

- PMLiVE

Sinovac’s COVID-19 vaccine receives WHO emergency use listing

Vaccine found to be 51% effective in preventing symptomatic disease, meeting the WHO's recommendation of at least 50% efficacy

- PMLiVE

J&J’s single-dose COVID-19 vaccine secures approval from the UK’s MHRA

Vaccine was found to be 67% effective in preventing COVID-19 infection in a phase 3 study

- PMLiVE

EMA authorises Pfizer/BioNTech’s COVID-19 vaccine for children aged 12 to 15

Clinical trial data recently showed that the vaccine is safe and effective in individuals in this age group

- PMLiVE

GSK, Vir’s COVID-19 mAb scores FDA emergency use approval

Interim phase 3 trial results found sotrovimab reduced the risk of hospitalisation or death by 85% compared to placebo

Digital Health for Improving Care in Disadvantaged Populations

Peter Wood (Co-founder & COO) and Dr. Raj Padwal (Co-founder & CEO) from mmHg Inc. explain how their Sphygmo virtual care system can be used to monitor blood pressure, glucose,...

Impetus Digital

The Future of Digital Pills

Valerie Sullivan, President and CEO at etectRx, dives into digital pills in healthcare and clinical research. Among many other things, we discuss how Pharma companies can benefit from the ability...

Impetus Digital

Improving Healthcare Access & Consumer Choice Through Digital Health

Erin Russell, Founder and CEO of Health Grizzly, shares her company’s approach to improving healthcare access and consumer choice through digital health. She also explores digital transformation in healthcare, how...

Impetus Digital

- PMLiVE

EU takes legal steps against AZ over delayed COVID-19 vaccine deliveries

Lawyers for the European Commission have asked the court to fine AZ €10m per infraction

- PMLiVE

Sanofi, GSK begin enrolment for phase 3 COVID-19 vaccine study

Study will investigate two formulations targeting the Wuhan strain and the South African variant

- PMLiVE

Novartis, Molecular Partners launch global study of novel COVID-19 drug

Initial positive phase 1 study results found that the drug was safe and well tolerated, with no significant adverse events reported

- PMLiVE

Launch excellence in COVID-19 times

By Stephanie Hall

- PMLiVE

Moderna’s COVID-19 vaccine offers high levels of protection for adolescents

The study results showed a vaccine efficacy of 100% starting 14 days after the second dose

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links